Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
New England Journal of Medicine2021Vol. 385(12), pp. 1078–1090
Citations Over TimeTop 1% of 2021 papers
Noam Barda, Noa Dagan, Yatir Ben‐Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac S. Kohane, Doron Netzer, Ben Y. Reis, Ran D. Balicer
Abstract
In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.).
Related Papers
- Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.(2003)
- → Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System(2022)23 cited
- → Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)(2021)13 cited
- → Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system(2024)1 cited
- → Multidimensional assessment of adverse events of finasteride: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024(2024)